174 related articles for article (PubMed ID: 36753044)
1. Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancer.
Castagnoli L; Corso S; Franceschini A; Raimondi A; Bellomo SE; Dugo M; Morano F; Prisciandaro M; Brich S; Belfiore A; Vingiani A; Di Bartolomeo M; Pruneri G; Tagliabue E; Giordano S; Pietrantonio F; Pupa SM
Cell Oncol (Dordr); 2023 Jun; 46(3):661-676. PubMed ID: 36753044
[TBL] [Abstract][Full Text] [Related]
2. A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines.
Puig T; Aguilar H; Cufí S; Oliveras G; Turrado C; Ortega-Gutiérrez S; Benhamú B; López-Rodríguez ML; Urruticoechea A; Colomer R
Breast Cancer Res; 2011; 13(6):R131. PubMed ID: 22177475
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
4. Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs.
Blancafort A; Giró-Perafita A; Oliveras G; Palomeras S; Turrado C; Campuzano Ò; Carrión-Salip D; Massaguer A; Brugada R; Palafox M; Gómez-Miragaya J; González-Suárez E; Puig T
PLoS One; 2015; 10(6):e0131241. PubMed ID: 26107737
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab Inhibits Growth of HER2-Negative Gastric Cancer Cells Through Gastrin-Initialized CCKBR Signaling.
Cui Y; Li SB; Peng XC; Wu J; Fu GH
Dig Dis Sci; 2015 Dec; 60(12):3631-41. PubMed ID: 26173505
[TBL] [Abstract][Full Text] [Related]
6. A new mechanism of trastuzumab resistance in gastric cancer: MACC1 promotes the Warburg effect via activation of the PI3K/AKT signaling pathway.
Liu J; Pan C; Guo L; Wu M; Guo J; Peng S; Wu Q; Zuo Q
J Hematol Oncol; 2016 Aug; 9(1):76. PubMed ID: 27581375
[TBL] [Abstract][Full Text] [Related]
7. Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells.
Jin Q; Yuan LX; Boulbes D; Baek JM; Wang YN; Gomez-Cabello D; Hawke DH; Yeung SC; Lee MH; Hortobagyi GN; Hung MC; Esteva FJ
Breast Cancer Res; 2010; 12(6):R96. PubMed ID: 21080941
[TBL] [Abstract][Full Text] [Related]
8. Effects of anti-proliferative lichen metabolite, protolichesterinic acid on fatty acid synthase, cell signalling and drug response in breast cancer cells.
Bessadóttir M; Skúladóttir EÁ; Gowan S; Eccles S; Ögmundsdóttir S; Ogmundsdóttir HM
Phytomedicine; 2014 Oct; 21(12):1717-24. PubMed ID: 25442282
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of B7-H3 and HER2 co-expression and therapeutic value of combination treatment in gastric cancer.
Shao X; Zhan S; Quan Q; Shen Y; Chen S; Zhang X; Li R; Liu M; Cao L
Int Immunopharmacol; 2022 Sep; 110():108988. PubMed ID: 35777267
[TBL] [Abstract][Full Text] [Related]
10. The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab.
Eto K; Iwatsuki M; Watanabe M; Ida S; Ishimoto T; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Baba H
Ann Surg Oncol; 2014 Jan; 21(1):343-50. PubMed ID: 24154840
[TBL] [Abstract][Full Text] [Related]
11. The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer.
Wang Q; Zhang X; Shen E; Gao J; Cao F; Wang X; Li Y; Tian T; Wang J; Chen Z; Wang J; Shen L
Cancer Lett; 2016 Sep; 380(1):20-30. PubMed ID: 27317872
[TBL] [Abstract][Full Text] [Related]
12. Cdc42-driven endosomal cholesterol transport promotes collateral resistance in HER2-positive gastric cancer.
Liang B; Wu Q; Wang Y; Shi Y; Sun F; Huang Q; Li G; Liu Y; Zhang S; Xu X; Yao G; Peng J; Zhai X; Wu J; Tan Y; Wu Z; Zhou R; Li S; Wu J; Yang M; Liao W; Shi M
Cancer Lett; 2024 Apr; 587():216702. PubMed ID: 38336288
[TBL] [Abstract][Full Text] [Related]
13. Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment.
Koschorke A; Faraci S; Giani D; Chiodoni C; Iorio E; Canese R; Colombo MP; Lamolinara A; Iezzi M; Ladomery M; Vernieri C; de Braud F; Di Nicola M; Tagliabue E; Castagnoli L; Pupa SM
Cell Oncol (Dordr); 2019 Dec; 42(6):815-828. PubMed ID: 31376137
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells.
Vazquez-Martin A; Colomer R; Brunet J; Lupu R; Menendez JA
Cell Prolif; 2008 Feb; 41(1):59-85. PubMed ID: 18211286
[TBL] [Abstract][Full Text] [Related]
15. Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer.
Mezynski MJ; Farrelly AM; Cremona M; Carr A; Morgan C; Workman J; Armstrong P; McAuley J; Madden S; Fay J; Sheehan KM; Kay EW; Holohan C; Elamin Y; Rafee S; Morris PG; Breathnach O; Grogan L; Hennessy BT; Toomey S
J Transl Med; 2021 May; 19(1):184. PubMed ID: 33933113
[TBL] [Abstract][Full Text] [Related]
16. Anchoring of hyaluronan glycocalyx to CD44 reduces sensitivity of HER2-positive gastric cancer cells to trastuzumab.
Chen S; Zhang G; Liu Y; Yang C; He Y; Guo Q; Du Y; Gao F
FEBS J; 2024 Apr; 291(8):1719-1731. PubMed ID: 38275079
[TBL] [Abstract][Full Text] [Related]
17. Porphyrin modified trastuzumab improves efficacy of HER2 targeted photodynamic therapy of gastric cancer.
Korsak B; Almeida GM; Rocha S; Pereira C; Mendes N; Osório H; Pereira PMR; Rodrigues JMM; Schneider RJ; Sarmento B; Tomé JPC; Oliveira C
Int J Cancer; 2017 Oct; 141(7):1478-1489. PubMed ID: 28639285
[TBL] [Abstract][Full Text] [Related]
18. Strengthening Gastric Cancer Therapy by Trastuzumab-Conjugated Nanoparticles with Simultaneous Encapsulation of Anti-MiR-21 and 5-Fluorouridine.
Hu N; Yin JF; Ji Z; Hong Y; Wu P; Bian B; Song Z; Li R; Liu Q; Wu F
Cell Physiol Biochem; 2017; 44(6):2158-2173. PubMed ID: 29241186
[TBL] [Abstract][Full Text] [Related]
19. Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients.
Vazquez-Martin A; Fernandez-Real JM; Oliveras-Ferraros C; Navarrete JM; Martin-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2009 Dec; 35(6):1369-76. PubMed ID: 19885560
[TBL] [Abstract][Full Text] [Related]
20. CD40×HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer.
Sun W; Wang X; Wang D; Lu L; Lin H; Zhang Z; Jia Y; Nie X; Liu T; Fu W
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
